Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution

Documenti analoghi

• Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
  di: Yi‐Ping Hung, et al.
  Pubblicazione: (2024)
• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
  di: Romeo Kuo‐Cheng Wu, et al.
  Pubblicazione: (2025)
• Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
  di: Terry Cheuk‐Fung Yip, et al.
  Pubblicazione: (2025)
• Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
  di: Mohammad Saeid Rezaee‐Zavareh, et al.
  Pubblicazione: (2026)
• Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
  di: Pranab M. Barman
  Pubblicazione: (2026)